237 related articles for article (PubMed ID: 16640173)
1. Integrated cardiovascular risk management for the future: lessons learned from the ASCOT trial.
Volpe M; Tocci G
Aging Clin Exp Res; 2005 Aug; 17(4 Suppl):46-53. PubMed ID: 16640173
[TBL] [Abstract][Full Text] [Related]
2. ESH-ESC guidelines for the management of hypertension.
Erdine S; Ari O; Zanchetti A; Cifkova R; Fagard R; Kjeldsen S; Mancia G; Poulter N; Rahn KH; Rodicio JL; Ruilope LM; Staessen J; van Zwieten P; Waeber B; Williams B
Herz; 2006 Jun; 31(4):331-8. PubMed ID: 16810473
[TBL] [Abstract][Full Text] [Related]
3. Rationale, design and patient baseline characteristics of OlmeSartan and calcium antagonists randomized (OSCAR) study: a study comparing the incidence of cardiovascular events between high-dose angiotensin II receptor blocker (ARB) monotherapy and combination therapy of ARB with calcium channel blocker in Japanese elderly high-risk hypertensive patients (ClinicalTrials. gov no. NCT00134160).
Ogawa H; Kim-Mitsuyama S; Jinnouchi T; Matsui K; Arakawa K
Hypertens Res; 2009 Jul; 32(7):575-80. PubMed ID: 19444280
[TBL] [Abstract][Full Text] [Related]
4. The future of antihypertensive treatment.
Israili ZH; Hernández-Hernández R; Valasco M
Am J Ther; 2007; 14(2):121-34. PubMed ID: 17414579
[TBL] [Abstract][Full Text] [Related]
5. 'Beyond blood pressure' means multiple risk factor intervention, not pleiotropic antihypertensive drugs.
Staessen JA; Thijs L; Li Y; Kuznetsova T; Richart T; Wang J; Birkenhäger WH
Curr Opin Cardiol; 2007 Jul; 22(4):335-43. PubMed ID: 17556887
[TBL] [Abstract][Full Text] [Related]
6. Atenolol as a comparator in outcome trials in hypertension: a correct choice in the past, but not for the future?
Dahlöf B; Devereux RB; Kjeldsen SE; Lyle PA; Zhang Z; Edelman JM
Blood Press; 2007; 16(1):6-12. PubMed ID: 17453746
[TBL] [Abstract][Full Text] [Related]
7. Learning from large cardiovascular clinical trials: classical cardiovascular risk factors.
Kempler P
Diabetes Res Clin Pract; 2005 Jun; 68 Suppl1():S43-7. PubMed ID: 15955374
[TBL] [Abstract][Full Text] [Related]
8. Long-term safety of antihypertensive therapy.
Grossman E; Messerli FH
Prog Cardiovasc Dis; 2006; 49(1):16-25. PubMed ID: 16867847
[TBL] [Abstract][Full Text] [Related]
9. Nifedipine gastrointestinal therapeutic system--hypertension management to improve cardiovascular outcomes.
Heagerty AM
Int J Clin Pract; 2005 Sep; 59(9):1112-9. PubMed ID: 16115193
[TBL] [Abstract][Full Text] [Related]
10. [New therapeutic outlooks in the treatment of the hypertensive patient].
Ambrosioni E; Bacchelli S; Borghi C
Ann Ital Med Int; 1995 Oct; 10 Suppl():78S-81S. PubMed ID: 8562273
[TBL] [Abstract][Full Text] [Related]
11. Pulse pressure reduction and cardiovascular protection.
Laurent S; Tropeano AI; Boutouyrie P
J Hypertens Suppl; 2006 May; 24(3):S13-8. PubMed ID: 16723861
[TBL] [Abstract][Full Text] [Related]
12. Aggressive blood pressure control and stroke prevention: role of calcium channel blockers.
Papadopoulos DP; Papademetriou V
J Hypertens; 2008 May; 26(5):844-52. PubMed ID: 18398322
[TBL] [Abstract][Full Text] [Related]
13. Management of hypertension in peripheral arterial disease: does the choice of drugs matter?
Singer DR; Kite A
Eur J Vasc Endovasc Surg; 2008 Jun; 35(6):701-8. PubMed ID: 18375152
[TBL] [Abstract][Full Text] [Related]
14. Total cardiovascular risk: a new treatment concept.
Mancia G
J Hypertens Suppl; 2006 Apr; 24(2):S17-24. PubMed ID: 16601556
[TBL] [Abstract][Full Text] [Related]
15. Discordant effects of beta-blockade on central aortic systolic and brachial systolic blood pressure: considerations beyond the cuff.
Epstein BJ; Anderson S
Pharmacotherapy; 2007 Sep; 27(9):1322-33. PubMed ID: 17723086
[TBL] [Abstract][Full Text] [Related]
16. Cardiovascular prevention (VI). Use of drugs in the primary prevention of arterial hypertension and dyslipidemia.
González-Juanatey JR; Mazón Ramos P
Rev Esp Cardiol; 2008 Aug; 61(8):861-79. PubMed ID: 18684369
[TBL] [Abstract][Full Text] [Related]
17. [Arterial hypertension and dyslipidemia in patients with chronic kidney disease (CKD). Anti-platelet aggregation. Goal oriented treatment].
Cases Amenós A; Goicoechea Diezhandiño M; de Alvaro Moreno F
Nefrologia; 2008; 28 Suppl 3():39-48. PubMed ID: 19018737
[TBL] [Abstract][Full Text] [Related]
18. A review of stroke in patients with hypertension and coronary artery disease: Focus on calcium channel blockers.
Bangalore S; Messerli FH
Int J Clin Pract; 2006 Oct; 60(10):1281-6. PubMed ID: 16942591
[TBL] [Abstract][Full Text] [Related]
19. Are current strategies for treating hypertension effective?
Sica DA
J Clin Hypertens (Greenwich); 2003; 5(3 Suppl 2):23-32. PubMed ID: 12826767
[TBL] [Abstract][Full Text] [Related]
20. Sex differences in risk factor control of treated hypertensives: a national primary healthcare-based study in Sweden.
Journath G; Hellénius ML; Petersson U; Theobald H; Nilsson PM;
Eur J Cardiovasc Prev Rehabil; 2008 Jun; 15(3):258-62. PubMed ID: 18525379
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
